Artículos del autor

solaci

Other

ACC 2023 | COORDINATE-DIABETES

Approximately only 2.7% of all diabetic patients with ischemic heart disease in the United States receive optimal...
solaci -
Other

ACC 2023 | A DUE-Study (Phase III)

In pulmonary hypertension (PHT), 10 mg macitentan plus 40 mg tadalafil is recommended as a safe combination therapy for...
solaci -
Acute coronary syndromes

ACC 2023 | Ultrasensitive Troponin I Monitoring with a Transdermal Wrist Device

Over the years, early diagnosis of myocardial ischemia has ranged from 0-to-3-h protocols to abbreviated guidelines with...
solaci -
Other

ACC 2023 | PULSE-AF

Catheter ablation is an effective treatment for patients with atrial fibrillation (AF) refractory to the standard medical...
solaci -
Chronic Coronary Syndromes

Mechanical Aspiration in ST Elevation ACS

In ST elevation ACS the preferred treatment is primary PCI. However, one its limitations is thrombus presence...
solaci -
Chronic Coronary Syndromes

ACC 2023 | Subanalysis of the REVIVED-BICS Study2

This study demonstrated that coronary angioplasty does not entail any benefit in chronic stable angina over optimal...
solaci -
Chronic Ischemic cardiopathy

ACC 2023 | YELLOW III Study. Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease

Dr. Kini presented the results of the YELLOW III Study where she analyzed the effect of evolocumab...
solaci -
Mitral valve

ACC 2023 | TRILUMINATE Pivotal: Edge-to-Edge Treatment in Patients with Tricuspid Regurgitation

Tricuspid regurgitation is a common and impairing disease. Optimal medical therapy (OMT) is limited, valve surgery is...
solaci -